ATRA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AT

Mkt Cap

$93.8M

Volume

17.65K

Next Earnings

November 11th

Loading chart

AT

ATRAAtara Biotherapeutics, Inc

ATRA

Pay with—

Available Balance0.00

AT

Mkt Cap

$96.9M

Volume

17.64K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRAA securities class action lawsuit has been filed against Atara Biotherapeutics for allegedly making false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that undermined FDA approval prospects for tabelecleucel. Investors who purchased securities between May 20, 2024 and January 9, 2026 may be eligible for compensation. The lead plaintiff deadline is May 22, 2026.GlobeNewswire Inc. · May 19, 2026

Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Atara Biotherapeutics, Inc. alleging that company executives made false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. The lawsuit covers investors who purchased Atara securities between May 20, 2024 and January 9, 2026.GlobeNewswire Inc. · May 18, 2026

DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsLaw Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Atara Biotherapeutics (ATRA), Coty Inc. (COTY), Super Micro Computer (SMCI), and ImmunityBio (IBRX). The lawsuits allege that defendants made false or misleading statements regarding their business operations and prospects. Lead plaintiff deadlines range from May 22-26, 2026.GlobeNewswire Inc. · May 14, 2026

Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Atara Biotherapeutics, Inc. alleging that company executives made false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. The lawsuit covers investors who purchased Atara securities between May 20, 2024 and January 9, 2026. The lead plaintiff deadline is May 22, 2026.GlobeNewswire Inc. · May 14, 2026

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm is seeking investors to join a class action lawsuit against Atara Biotherapeutics for alleged securities fraud. The company allegedly made false and misleading statements regarding manufacturing problems and deficiencies in its ALLELE study for tabelecleucel, overstating the drug's prospects and concealing regulatory risks. Investors who purchased securities between May 20, 2024 and January 9, 2026 are encouraged to participate.GlobeNewswire Inc. · May 14, 2026

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitAtara Biotherapeutics faces a class action securities fraud lawsuit after the FDA rejected its Epstein-Barr virus treatment (tabelecleucel/EBVALLO) twice due to manufacturing issues and inadequate trial design. The stock plummeted 40.5% on January 16, 2025, and another 57% on January 12, 2026, following the rejections. Shareholders who purchased ATRA securities between May 20, 2024 and January 9, 2026 are urged to file lead plaintiff motions by May 22, 2026.GlobeNewswire Inc. · May 12, 2026

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRARosen Law Firm is soliciting investors in Atara Biotherapeutics who purchased securities between May 20, 2024 and January 9, 2026 to join a class action lawsuit. The lawsuit alleges that Atara made false statements regarding manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely, and that regulatory prospects were overstated. The lead plaintiff deadline is May 22, 2026.GlobeNewswire Inc. · May 11, 2026

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Graphic Packaging Holding Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – GPKRosen Law Firm has filed class action lawsuits on behalf of investors in Graphic Packaging Holding Company and other firms. The lawsuit alleges that Graphic Packaging made false statements regarding inventory management, demand, costs, and financial guidance during the Class Period (February 4, 2025 - February 2, 2026). Investors who purchased securities during this period may be eligible for compensation. The deadline to serve as lead plaintiff is July 6, 2026.GlobeNewswire Inc. · May 11, 2026

Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights – ATRALevi & Korsinsky announces a class action securities lawsuit against Atara Biotherapeutics for alleged fraud between May 20, 2024 and January 9, 2026. The complaint alleges the company made false statements about manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely, while overstating regulatory prospects. Investors who suffered losses during this period can request lead plaintiff status by May 22, 2026.GlobeNewswire Inc. · May 11, 2026

UPST Investor Alert: Upstart Holdings Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Inflated AI Projections: Levi & KorsinskyUpstart Holdings faces a securities class action lawsuit after allegedly inflating AI model performance projections. The company's flagship AI underwriting model suppressed loan approvals in Q3 2025, leading to a $4.49 per share (9.71%) decline and a $44 million revenue guidance cut. Institutional investors who purchased shares between May 14, 2025 and November 4, 2025 may seek lead plaintiff status by June 8, 2026.GlobeNewswire Inc. · May 11, 2026

to start trading

AT

ATRAAtara Biotherapeutics, Inc

ATRA

Pay with—

Available Balance0.00

Your PositionYou don't own any ATRA yet.

Related Tickers

Earnings